"Naszą misją jest ułatwianie dostępu do nowoczesnych terapii leczniczych. Nowe leki to szansa na poprawę jakości życia dla pacjenta i przyszłych pokoleń. KO-MED Centra Kliniczne to sieć nowoczesnych i prężnie działających ośrodków, które każdego dnia przyjmują dziesiątki pacjentów z całej Polski. Naszą misją jest realizacja projektów badawczych, które stanowią szansę na odzyskanie zdrowia i przyczyniają się do rozwoju medycyny. Działalność prowadzimy od 20 lat, mając na koncie setki przeprowadzonych badań klinicznych. KO-MED Centra Kliniczne to gwarancja wysokiej jakości, efektywności i bezpieczeństwa prowadzonych badań. Na pierwszym miejscu zawsze stawiamy dobro pacjenta."

During the past decade, KO-MED Centra Kliniczne Staszow conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 12 clinical trials were completed, i.e. on average, 85.7% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 8 clinical trials were completed. i.e. 400% of trials that started reached the finish line.

Out of the total clinical trials conducted in "KO-MED Centra Kliniczne Staszow" #1 sponsor was "Boehringer Ingelheim" with 3 trials, followed by "Celgene" with 2 trials sponsored, "Pfizer" with 2 trials sponsored, "R-Pharm International, LLC" with 2 trials sponsored and "Reistone Biopharma Company Limited" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "KO-MED Centra Kliniczne Staszow" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "OCT Clinical Trials" with 2 trials as a collaborator, "Brigham and Women's Hospital" with 1 trials as a collaborator, "IQVIA Pvt. Ltd" with 1 trials as a collaborator and "Quintiles, Inc." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "KO-MED Centra Kliniczne Staszow" are "Ulcerative Colitis" (5 trials), "Rheumatoid Arthritis" (3 trials), "Cardiovascular Disease" (2 trials), "Crohn's Disease" (2 trials) and "Heart Failure" (2 trials). Many other conditions were trialed in "KO-MED Centra Kliniczne Staszow" in a lesser frequency.

Most popular intervention types in "KO-MED Centra Kliniczne Staszow" are "Drug" (16 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Empagliflozin" (2 trials), "RPC1063" (2 trials), "SHR0302" (2 trials) and "bococizumab (PF-04950615)" (2 trials). Other intervention names were less common.

The vast majority of trials in "KO-MED Centra Kliniczne Staszow" are 17 trials for "All" genders.

Currently, there are NaN active trials in "KO-MED Centra Kliniczne Staszow". undefined are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in KO-MED Centra Kliniczne Staszow, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in KO-MED Centra Kliniczne Staszow, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 12 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".